Benzinga · Nov 17, 2026
HC Wainwright & Co. Reiterates Buy on Oculis Holding, Maintains $39 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates Oculis Holding (NASDAQ:OCS) with a Buy and maintains $39 price target.
NASDAQ · OCS
Healthcare · Biotechnology
$7.44
Up+$0.05 (+0.68%)
Updated Nov 20, 2026, 9:42 AM
SID Score
3.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · OCS
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 19, 2026
OCS closed at $7.44 after 21 trading sessions, down 8.03% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 19, 2026 | $7.46 | $7.50 | $7.18 | $7.44 | 153.99K |
| Nov 18, 2026 | $7.56 | $7.75 | $7.20 | $7.39 | 311.56K |
| Nov 17, 2026 | $7.76 | $7.815 | $7.09 | $7.51 | 239.99K |
| Nov 16, 2026 | $7.97 | $8.21 | $7.54 | $7.63 | 211.17K |
| Nov 13, 2026 | $7.51 | $7.68 | $7.28 | $7.64 | 183.98K |
| Nov 12, 2026 | $7.60 | $7.86 | $7.33 | $7.50 | 299.11K |
| Nov 11, 2026 | $7.67 | $8.025 | $7.60 | $7.61 | 227.36K |
| Nov 10, 2026 | $7.72 | $8.04 | $7.54 | $7.59 | 266.85K |
| Nov 9, 2026 | $7.67 | $8.04 | $7.49 | $7.76 | 339.86K |
| Nov 6, 2026 | $6.83 | $7.64 | $6.81 | $7.49 | 404.09K |
| Nov 5, 2026 | $7.30 | $7.8542 | $6.78 | $6.83 | 371.65K |
| Nov 4, 2026 | $7.60 | $7.89 | $6.80 | $7.28 | 550.22K |
| Nov 3, 2026 | $7.72 | $7.87 | $7.29 | $7.63 | 541.79K |
| Nov 2, 2026 | $8.38 | $8.539 | $7.66 | $7.71 | 246.35K |
| Oct 30, 2026 | $8.19 | $8.84 | $8.19 | $8.26 | 309.7K |
| Oct 29, 2026 | $8.09 | $8.53 | $8.09 | $8.24 | 263.73K |
| Oct 28, 2026 | $7.80 | $8.05 | $7.72 | $7.98 | 220.03K |
| Oct 27, 2026 | $7.92 | $8.145 | $7.68 | $7.83 | 189.29K |
| Oct 26, 2026 | $7.88 | $8.025 | $7.65 | $7.96 | 206.97K |
| Oct 23, 2026 | $8.04 | $8.07 | $7.82 | $7.90 | 294.73K |
| Oct 22, 2026 | $7.77 | $8.3099 | $7.725 | $8.09 | 427.89K |
The latest Smart Investors Daily articles mentioning OCS.
Company
Market Activity
Research & News
OCS research
Company profile and research snapshot.
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 17, 2026 | HC Wainwright & Co. | Buy | — |
| Nov 4, 2026 | Guggenheim | Buy | — |
| Oct 23, 2026 | HC Wainwright & Co. | Buy | — |
| Sep 18, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 14, 2026 | JP Morgan | Overweight | — |
No generated briefing is available yet.
Benzinga · Nov 17, 2026
HC Wainwright & Co. analyst Yi Chen reiterates Oculis Holding (NASDAQ:OCS) with a Buy and maintains $39 price target.
Yahoo · Nov 16, 2026
FDA IND clearance opens a new era for Oculis in neurology, initiating clinical development in acute MS relapses by building directly upon the positive Phase 2 ACUITY trial and ongoing PIONEER program in optic neuritis Oculis will host an R&D Day on December 8, 2026, to provide further updates on the development program for Privosegtor in acute MS relapses and the ongoing PIONEER program in optic neuropathies ZUG, Switzerland, November 16, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Ocu
Benzinga · Nov 16, 2026
FDA IND clearance opens a new era for Oculis in neurology, initiating clinical development in acute MS relapses by building directly upon the positive Phase 2 ACUITY trial and ongoing PIONEER program in optic
Yahoo · Nov 13, 2026
ZUG, Switzerland, Nov. 13, 2026 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting and settlement of RSUs previously granted to directors of the Company. Attachments Notification of managers' transaction - Anthony Rosenberg - 13 November 2026 RSU vest Notification of managers' transaction - Christina Ackermann - 13 November 2026 RSU vest Notification of managers' transaction - Arshad Khanani - 13 November 2026 RSU vest Notification of managers' transaction - Robert Warner - 13
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning OCS.